APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Factor Xa Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral Factor Xa Inhibitors Market Analysis and Forecast 2026-2032

29 December 2025200 pages

Choose your research edition.

Industry ResearchOral Factor Xa Inhibitors Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Oral Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Factor Xa Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral Factor Xa Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Oral Factor Xa Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral Factor Xa Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral Factor Xa Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral Factor Xa Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Oral Factor Xa Inhibitors include Accord Healthcare, Apotex, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Lupin, Mylan and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Oral Factor Xa Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral Factor Xa Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Oral Factor Xa Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Factor Xa Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral Factor Xa Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Oral Factor Xa Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Oral Factor Xa Inhibitors Segment by Company

Accord Healthcare

Apotex

Bayer

Bristol Myers Squibb

Daiichi Sankyo

Janssen Pharmaceuticals

Lupin

Mylan

Pfizer

Zydus

HEC Pharma

Hansoh Pharma

Huahai Pharmaceutical

Shanghai Huilun Pharmaceutical

Qilu Pharmaceutical

Cspc Ouyi Pharmaceutical

Yangtze River Pharmaceutical

Zhejiang Hisun Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Oral Factor Xa Inhibitors Segment by Type

Edoxaban

Rivaroxaban

Apixaban

Oral Factor Xa Inhibitors Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Oral Factor Xa Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Factor Xa Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Oral Factor Xa Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Oral Factor Xa Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Factor Xa Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral Factor Xa Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Edoxaban Major Manufacturers Table 3. Rivaroxaban Major Manufacturers Table 4. Apixaban Major Manufacturers Table 5. Global Oral Factor Xa Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Pulmonary Embolism Major Manufacturers Table 7. Deep Vein Thrombosis Major Manufacturers Table 8. Atrial Fibrillation Major Manufacturers Table 9. Other Major Manufacturers Table 10. Oral Factor Xa Inhibitors Industry Trends Table 11. Oral Factor Xa Inhibitors Industry Drivers Table 12. Oral Factor Xa Inhibitors Industry Opportunities and Challenges Table 13. Oral Factor Xa Inhibitors Industry Restraints Table 14. Global Oral Factor Xa Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Oral Factor Xa Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Oral Factor Xa Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2021-2026) Table 18. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2027-2032) Table 19. Global Oral Factor Xa Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Oral Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units) Table 21. Global Oral Factor Xa Inhibitors Sales by Region (2027-2032) & (K Units) Table 22. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2021-2026) Table 23. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2027-2032) Table 24. Global Oral Factor Xa Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Oral Factor Xa Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Oral Factor Xa Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Oral Factor Xa Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 28. Global Oral Factor Xa Inhibitors Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Oral Factor Xa Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Oral Factor Xa Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Oral Factor Xa Inhibitors Manufacturers, Product Type & Application Table 32. Global Oral Factor Xa Inhibitors Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Oral Factor Xa Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Oral Factor Xa Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Oral Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2026) Table 39. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2027-2032) Table 40. Global Oral Factor Xa Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 42. Global Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 43. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026) Table 44. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2027-2032) Table 45. Global Oral Factor Xa Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 46. Global Oral Factor Xa Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 47. Global Oral Factor Xa Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Oral Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2026) Table 51. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2027-2032) Table 52. Global Oral Factor Xa Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 54. Global Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 55. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026) Table 56. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2027-2032) Table 57. Global Oral Factor Xa Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 58. Global Oral Factor Xa Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 59. Accord Healthcare Company Information Table 60. Accord Healthcare Business Overview Table 61. Accord Healthcare Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio Table 63. Accord Healthcare Recent Development Table 64. Apotex Company Information Table 65. Apotex Business Overview Table 66. Apotex Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Apotex Oral Factor Xa Inhibitors Product Portfolio Table 68. Apotex Recent Development Table 69. Bayer Company Information Table 70. Bayer Business Overview Table 71. Bayer Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Bayer Oral Factor Xa Inhibitors Product Portfolio Table 73. Bayer Recent Development Table 74. Bristol Myers Squibb Company Information Table 75. Bristol Myers Squibb Business Overview Table 76. Bristol Myers Squibb Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio Table 78. Bristol Myers Squibb Recent Development Table 79. Daiichi Sankyo Company Information Table 80. Daiichi Sankyo Business Overview Table 81. Daiichi Sankyo Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio Table 83. Daiichi Sankyo Recent Development Table 84. Janssen Pharmaceuticals Company Information Table 85. Janssen Pharmaceuticals Business Overview Table 86. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio Table 88. Janssen Pharmaceuticals Recent Development Table 89. Lupin Company Information Table 90. Lupin Business Overview Table 91. Lupin Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Lupin Oral Factor Xa Inhibitors Product Portfolio Table 93. Lupin Recent Development Table 94. Mylan Company Information Table 95. Mylan Business Overview Table 96. Mylan Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Mylan Oral Factor Xa Inhibitors Product Portfolio Table 98. Mylan Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Pfizer Oral Factor Xa Inhibitors Product Portfolio Table 103. Pfizer Recent Development Table 104. Zydus Company Information Table 105. Zydus Business Overview Table 106. Zydus Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Zydus Oral Factor Xa Inhibitors Product Portfolio Table 108. Zydus Recent Development Table 109. HEC Pharma Company Information Table 110. HEC Pharma Business Overview Table 111. HEC Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. HEC Pharma Oral Factor Xa Inhibitors Product Portfolio Table 113. HEC Pharma Recent Development Table 114. Hansoh Pharma Company Information Table 115. Hansoh Pharma Business Overview Table 116. Hansoh Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio Table 118. Hansoh Pharma Recent Development Table 119. Huahai Pharmaceutical Company Information Table 120. Huahai Pharmaceutical Business Overview Table 121. Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 123. Huahai Pharmaceutical Recent Development Table 124. Shanghai Huilun Pharmaceutical Company Information Table 125. Shanghai Huilun Pharmaceutical Business Overview Table 126. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 128. Shanghai Huilun Pharmaceutical Recent Development Table 129. Qilu Pharmaceutical Company Information Table 130. Qilu Pharmaceutical Business Overview Table 131. Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 133. Qilu Pharmaceutical Recent Development Table 134. Cspc Ouyi Pharmaceutical Company Information Table 135. Cspc Ouyi Pharmaceutical Business Overview Table 136. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 138. Cspc Ouyi Pharmaceutical Recent Development Table 139. Yangtze River Pharmaceutical Company Information Table 140. Yangtze River Pharmaceutical Business Overview Table 141. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 143. Yangtze River Pharmaceutical Recent Development Table 144. Zhejiang Hisun Pharmaceutical Company Information Table 145. Zhejiang Hisun Pharmaceutical Business Overview Table 146. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 148. Zhejiang Hisun Pharmaceutical Recent Development Table 149. Chia Tai Tianqing Pharmaceutical Company Information Table 150. Chia Tai Tianqing Pharmaceutical Business Overview Table 151. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 153. Chia Tai Tianqing Pharmaceutical Recent Development Table 154. North America Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 155. North America Oral Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 156. North America Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 157. North America Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 158. North America Oral Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 159. North America Oral Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 160. North America Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 161. North America Oral Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 162. North America Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 163. North America Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 164. North America Oral Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 165. North America Oral Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 166. North America Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. North America Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 168. North America Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 169. North America Oral Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 170. North America Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 171. North America Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 172. North America Oral Factor Xa Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 173. North America Oral Factor Xa Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 174. United States Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 175. Canada Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 176. Mexico Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 177. Europe Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 178. Europe Oral Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 179. Europe Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 180. Europe Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 181. Europe Oral Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 182. Europe Oral Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 183. Europe Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 184. Europe Oral Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 185. Europe Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 186. Europe Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 187. Europe Oral Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 188. Europe Oral Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 189. Europe Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 190. Europe Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 191. Europe Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 192. Europe Oral Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 193. Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 194. Europe Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 195. Europe Oral Factor Xa Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 196. Europe Oral Factor Xa Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 197. Germany Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 198. France Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 199. U.K. Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 200. Italy Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 201. Russia Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 202. Spain Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 203. Netherlands Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 204. Switzerland Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 205. Sweden Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 206. Poland Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 207. China Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 208. China Oral Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 209. China Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 210. China Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 211. China Oral Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 212. China Oral Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 213. China Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 214. China Oral Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 215. China Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 216. China Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 217. China Oral Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 218. China Oral Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 219. Asia Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 220. Asia Oral Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 221. Asia Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 222. Asia Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 223. Asia Oral Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 224. Asia Oral Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 225. Asia Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 226. Asia Oral Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 227. Asia Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 228. Asia Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 229. Asia Oral Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 230. Asia Oral Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 231. Asia Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 232. Asia Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 233. Asia Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 234. Asia Oral Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 235. Asia Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 236. Asia Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 237. Asia Oral Factor Xa Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 238. Asia Oral Factor Xa Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 239. Japan Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 240. South Korea Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 241. India Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 242. Australia Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 243. Taiwan Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 244. Southeast Asia Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 245. SAMEA Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 246. SAMEA Oral Factor Xa Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 247. SAMEA Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 248. SAMEA Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 249. SAMEA Oral Factor Xa Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 250. SAMEA Oral Factor Xa Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 251. SAMEA Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 252. SAMEA Oral Factor Xa Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 253. SAMEA Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 254. SAMEA Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 255. SAMEA Oral Factor Xa Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 256. SAMEA Oral Factor Xa Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 257. SAMEA Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 258. SAMEA Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 259. SAMEA Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 260. SAMEA Oral Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 261. SAMEA Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 262. SAMEA Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 263. SAMEA Oral Factor Xa Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 264. SAMEA Oral Factor Xa Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 265. Brazil Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 266. Argentina Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 267. Chile Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 268. Colombia Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 269. Peru Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 270. Saudi Arabia Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 271. Israel Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 272. UAE Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 273. Turkey Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 274. Iran Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 275. Egypt Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Table 276. Key Raw Materials Table 277. Raw Materials Key Suppliers Table 278. Oral Factor Xa Inhibitors Distributors List Table 279. Oral Factor Xa Inhibitors Customers List Table 280. Research Programs/Design for This Report Table 281. Authors List of This Report Table 282. Secondary Sources Table 283. Primary Sources List of Figures Figure 1. Oral Factor Xa Inhibitors Image Figure 2. Global Oral Factor Xa Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Factor Xa Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Edoxaban Image Figure 5. Rivaroxaban Image Figure 6. Apixaban Image Figure 7. Global Oral Factor Xa Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Oral Factor Xa Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 9. Pulmonary Embolism Image Figure 10. Deep Vein Thrombosis Image Figure 11. Atrial Fibrillation Image Figure 12. Other Image Figure 13. Global Oral Factor Xa Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Figure 15. Global Oral Factor Xa Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Oral Factor Xa Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2021-2032) Figure 18. Global Oral Factor Xa Inhibitors Sales (2021-2032) & (K Units) Figure 19. Global Oral Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Oral Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 22. Europe Oral Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 23. China Oral Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Oral Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Oral Factor Xa Inhibitors Sales YoY (2021-2032) & (K Units) Figure 26. Global Oral Factor Xa Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Oral Factor Xa Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Oral Factor Xa Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Oral Factor Xa Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2032) Figure 32. Global Oral Factor Xa Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Oral Factor Xa Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2032) Figure 35. Global Oral Factor Xa Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Oral Factor Xa Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2032) Figure 38. Global Oral Factor Xa Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Oral Factor Xa Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2032) Figure 41. North America Oral Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 42. North America Oral Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 43. North America Oral Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 44. North America Oral Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 45. North America Oral Factor Xa Inhibitors Revenue Share by Country (2021-2032) Figure 46. North America Oral Factor Xa Inhibitors Sales Share by Country (2021-2032) Figure 47. Europe Oral Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 48. Europe Oral Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 49. Europe Oral Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 50. Europe Oral Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 51. Europe Oral Factor Xa Inhibitors Revenue Share by Country (2021-2032) Figure 52. Europe Oral Factor Xa Inhibitors Sales Share by Country (2021-2032) Figure 53. China Oral Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 54. China Oral Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 55. China Oral Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 56. China Oral Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 57. Asia Oral Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 58. Asia Oral Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 59. Asia Oral Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 60. Asia Oral Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 61. Asia Oral Factor Xa Inhibitors Revenue Share by Country (2021-2032) Figure 62. Asia Oral Factor Xa Inhibitors Sales Share by Country (2021-2032) Figure 63. SAMEA Oral Factor Xa Inhibitors Revenue Share by Type (2021-2032) Figure 64. SAMEA Oral Factor Xa Inhibitors Sales Share by Type (2021-2032) Figure 65. SAMEA Oral Factor Xa Inhibitors Revenue Share by Application (2021-2032) Figure 66. SAMEA Oral Factor Xa Inhibitors Sales Share by Application (2021-2032) Figure 67. SAMEA Oral Factor Xa Inhibitors Revenue Share by Country (2021-2032) Figure 68. SAMEA Oral Factor Xa Inhibitors Sales Share by Country (2021-2032) Figure 69. Oral Factor Xa Inhibitors Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Oral Factor Xa Inhibitors Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Edoxaban
  • Rivaroxaban
  • Apixaban
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Bayer
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • Janssen Pharmaceuticals
  • Lupin
  • Mylan
  • Pfizer
  • Zydus
  • HEC Pharma
  • Hansoh Pharma
  • Huahai Pharmaceutical
  • Shanghai Huilun Pharmaceutical
  • Qilu Pharmaceutical
  • Cspc Ouyi Pharmaceutical
  • Yangtze River Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral Factor Xa Inhibitors Market by Type
  3. 1.2.1 Global Oral Factor Xa Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Edoxaban
  5. 1.2.3 Rivaroxaban
  6. 1.2.4 Apixaban
  7. 1.3 Oral Factor Xa Inhibitors Market by Application
  8. 1.3.1 Global Oral Factor Xa Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Pulmonary Embolism
  10. 1.3.3 Deep Vein Thrombosis
  11. 1.3.4 Atrial Fibrillation
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Oral Factor Xa Inhibitors Market Dynamics
  1. 2.1 Oral Factor Xa Inhibitors Industry Trends
  2. 2.2 Oral Factor Xa Inhibitors Industry Drivers
  3. 2.3 Oral Factor Xa Inhibitors Industry Opportunities and Challenges
  4. 2.4 Oral Factor Xa Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Oral Factor Xa Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Oral Factor Xa Inhibitors Revenue by Region
  3. 3.2.1 Global Oral Factor Xa Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral Factor Xa Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global Oral Factor Xa Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Oral Factor Xa Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Oral Factor Xa Inhibitors Sales by Region
  9. 3.4.1 Global Oral Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Oral Factor Xa Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global Oral Factor Xa Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global Oral Factor Xa Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Oral Factor Xa Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global Oral Factor Xa Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Oral Factor Xa Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Oral Factor Xa Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral Factor Xa Inhibitors Sales by Manufacturers
  6. 4.2.1 Global Oral Factor Xa Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Oral Factor Xa Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Oral Factor Xa Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Oral Factor Xa Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Oral Factor Xa Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Oral Factor Xa Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Oral Factor Xa Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global Oral Factor Xa Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Oral Factor Xa Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 Oral Factor Xa Inhibitors Tier 1, Tier 2, and Tier 3
5 Oral Factor Xa Inhibitors Market by Type
  1. 5.1 Global Oral Factor Xa Inhibitors Revenue by Type
  2. 5.1.1 Global Oral Factor Xa Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Oral Factor Xa Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Oral Factor Xa Inhibitors Sales by Type
  6. 5.2.1 Global Oral Factor Xa Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Factor Xa Inhibitors Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global Oral Factor Xa Inhibitors Price by Type
6 Oral Factor Xa Inhibitors Market by Application
  1. 6.1 Global Oral Factor Xa Inhibitors Revenue by Application
  2. 6.1.1 Global Oral Factor Xa Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Oral Factor Xa Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Oral Factor Xa Inhibitors Sales by Application
  6. 6.2.1 Global Oral Factor Xa Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Oral Factor Xa Inhibitors Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global Oral Factor Xa Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Accord Healthcare
  2. 7.1.1 Accord Healthcare Company Information
  3. 7.1.2 Accord Healthcare Business Overview
  4. 7.1.3 Accord Healthcare Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio
  6. 7.1.5 Accord Healthcare Recent Developments
  7. 7.2 Apotex
  8. 7.2.1 Apotex Company Information
  9. 7.2.2 Apotex Business Overview
  10. 7.2.3 Apotex Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Apotex Oral Factor Xa Inhibitors Product Portfolio
  12. 7.2.5 Apotex Recent Developments
  13. 7.3 Bayer
  14. 7.3.1 Bayer Company Information
  15. 7.3.2 Bayer Business Overview
  16. 7.3.3 Bayer Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Bayer Oral Factor Xa Inhibitors Product Portfolio
  18. 7.3.5 Bayer Recent Developments
  19. 7.4 Bristol Myers Squibb
  20. 7.4.1 Bristol Myers Squibb Company Information
  21. 7.4.2 Bristol Myers Squibb Business Overview
  22. 7.4.3 Bristol Myers Squibb Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio
  24. 7.4.5 Bristol Myers Squibb Recent Developments
  25. 7.5 Daiichi Sankyo
  26. 7.5.1 Daiichi Sankyo Company Information
  27. 7.5.2 Daiichi Sankyo Business Overview
  28. 7.5.3 Daiichi Sankyo Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio
  30. 7.5.5 Daiichi Sankyo Recent Developments
  31. 7.6 Janssen Pharmaceuticals
  32. 7.6.1 Janssen Pharmaceuticals Company Information
  33. 7.6.2 Janssen Pharmaceuticals Business Overview
  34. 7.6.3 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio
  36. 7.6.5 Janssen Pharmaceuticals Recent Developments
  37. 7.7 Lupin
  38. 7.7.1 Lupin Company Information
  39. 7.7.2 Lupin Business Overview
  40. 7.7.3 Lupin Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Lupin Oral Factor Xa Inhibitors Product Portfolio
  42. 7.7.5 Lupin Recent Developments
  43. 7.8 Mylan
  44. 7.8.1 Mylan Company Information
  45. 7.8.2 Mylan Business Overview
  46. 7.8.3 Mylan Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Mylan Oral Factor Xa Inhibitors Product Portfolio
  48. 7.8.5 Mylan Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Oral Factor Xa Inhibitors Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Zydus
  56. 7.10.1 Zydus Company Information
  57. 7.10.2 Zydus Business Overview
  58. 7.10.3 Zydus Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Zydus Oral Factor Xa Inhibitors Product Portfolio
  60. 7.10.5 Zydus Recent Developments
  61. 7.11 HEC Pharma
  62. 7.11.1 HEC Pharma Company Information
  63. 7.11.2 HEC Pharma Business Overview
  64. 7.11.3 HEC Pharma Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 HEC Pharma Oral Factor Xa Inhibitors Product Portfolio
  66. 7.11.5 HEC Pharma Recent Developments
  67. 7.12 Hansoh Pharma
  68. 7.12.1 Hansoh Pharma Company Information
  69. 7.12.2 Hansoh Pharma Business Overview
  70. 7.12.3 Hansoh Pharma Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio
  72. 7.12.5 Hansoh Pharma Recent Developments
  73. 7.13 Huahai Pharmaceutical
  74. 7.13.1 Huahai Pharmaceutical Company Information
  75. 7.13.2 Huahai Pharmaceutical Business Overview
  76. 7.13.3 Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  78. 7.13.5 Huahai Pharmaceutical Recent Developments
  79. 7.14 Shanghai Huilun Pharmaceutical
  80. 7.14.1 Shanghai Huilun Pharmaceutical Company Information
  81. 7.14.2 Shanghai Huilun Pharmaceutical Business Overview
  82. 7.14.3 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  84. 7.14.5 Shanghai Huilun Pharmaceutical Recent Developments
  85. 7.15 Qilu Pharmaceutical
  86. 7.15.1 Qilu Pharmaceutical Company Information
  87. 7.15.2 Qilu Pharmaceutical Business Overview
  88. 7.15.3 Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  90. 7.15.5 Qilu Pharmaceutical Recent Developments
  91. 7.16 Cspc Ouyi Pharmaceutical
  92. 7.16.1 Cspc Ouyi Pharmaceutical Company Information
  93. 7.16.2 Cspc Ouyi Pharmaceutical Business Overview
  94. 7.16.3 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  96. 7.16.5 Cspc Ouyi Pharmaceutical Recent Developments
  97. 7.17 Yangtze River Pharmaceutical
  98. 7.17.1 Yangtze River Pharmaceutical Company Information
  99. 7.17.2 Yangtze River Pharmaceutical Business Overview
  100. 7.17.3 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  102. 7.17.5 Yangtze River Pharmaceutical Recent Developments
  103. 7.18 Zhejiang Hisun Pharmaceutical
  104. 7.18.1 Zhejiang Hisun Pharmaceutical Company Information
  105. 7.18.2 Zhejiang Hisun Pharmaceutical Business Overview
  106. 7.18.3 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  108. 7.18.5 Zhejiang Hisun Pharmaceutical Recent Developments
  109. 7.19 Chia Tai Tianqing Pharmaceutical
  110. 7.19.1 Chia Tai Tianqing Pharmaceutical Company Information
  111. 7.19.2 Chia Tai Tianqing Pharmaceutical Business Overview
  112. 7.19.3 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  114. 7.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Oral Factor Xa Inhibitors Market Size by Type
  2. 8.1.1 North America Oral Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America Oral Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America Oral Factor Xa Inhibitors Price by Type (2021-2032)
  5. 8.2 North America Oral Factor Xa Inhibitors Market Size by Application
  6. 8.2.1 North America Oral Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America Oral Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America Oral Factor Xa Inhibitors Price by Application (2021-2032)
  9. 8.3 North America Oral Factor Xa Inhibitors Market Size by Country
  10. 8.3.1 North America Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Oral Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Oral Factor Xa Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Oral Factor Xa Inhibitors Market Size by Type
  2. 9.1.1 Europe Oral Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe Oral Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe Oral Factor Xa Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe Oral Factor Xa Inhibitors Market Size by Application
  6. 9.2.1 Europe Oral Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe Oral Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe Oral Factor Xa Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe Oral Factor Xa Inhibitors Market Size by Country
  10. 9.3.1 Europe Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Oral Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Oral Factor Xa Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Oral Factor Xa Inhibitors Market Size by Type
  2. 10.1.1 China Oral Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China Oral Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China Oral Factor Xa Inhibitors Price by Type (2021-2032)
  5. 10.2 China Oral Factor Xa Inhibitors Market Size by Application
  6. 10.2.1 China Oral Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China Oral Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China Oral Factor Xa Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral Factor Xa Inhibitors Market Size by Type
  2. 11.1.1 Asia Oral Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia Oral Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia Oral Factor Xa Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia Oral Factor Xa Inhibitors Market Size by Application
  6. 11.2.1 Asia Oral Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia Oral Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia Oral Factor Xa Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia Oral Factor Xa Inhibitors Market Size by Country
  10. 11.3.1 Asia Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Oral Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Oral Factor Xa Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral Factor Xa Inhibitors Market Size by Type
  2. 12.1.1 SAMEA Oral Factor Xa Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Oral Factor Xa Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Oral Factor Xa Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA Oral Factor Xa Inhibitors Market Size by Application
  6. 12.2.1 SAMEA Oral Factor Xa Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Oral Factor Xa Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Oral Factor Xa Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA Oral Factor Xa Inhibitors Market Size by Country
  10. 12.3.1 SAMEA Oral Factor Xa Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Oral Factor Xa Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Oral Factor Xa Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Oral Factor Xa Inhibitors Value Chain Analysis
  2. 13.1.1 Oral Factor Xa Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Oral Factor Xa Inhibitors Production Mode & Process
  6. 13.2 Oral Factor Xa Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Oral Factor Xa Inhibitors Distributors
  9. 13.2.3 Oral Factor Xa Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst